2006
Reinfection and relapse in early Lyme disease.
Krause PJ, Foley DT, Burke GS, Christianson D, Closter L, Spielman A. Reinfection and relapse in early Lyme disease. American Journal Of Tropical Medicine And Hygiene 2006, 75: 1090-4. PMID: 17172372, DOI: 10.4269/ajtmh.2006.75.1090.Peer-Reviewed Original ResearchConceptsEarly Lyme diseaseRecurrent episodesLyme diseaseErythema migransStandard antibiotic therapyInitial rashPrompt administrationAntibiotic therapyClinical manifestationsPrevent relapsePersistent infectionBody sitesDiseaseSequential episodesSpecific antibodiesEndemic sitesEpisodesReinfectionRelapseDetectable levelsFrequent contactVector ticksYearsRashSerology
2001
Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial
Sikand V, Halsey N, Krause P, Sood S, Geller R, Van Hoecke C, Buscarino C, Parenti D. Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial. Pediatrics 2001, 108: 123-128. PMID: 11433064, DOI: 10.1542/peds.108.1.123.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntigens, SurfaceArthralgiaBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupChildChild, PreschoolEdemaErythemaExanthemaFatigueFemaleFeverHeadacheHumansImmunoglobulin GIncidenceInjectionsLipoproteinsLyme DiseaseLyme Disease VaccinesMalePainSeverity of Illness IndexTime FactorsUnited StatesConceptsLocal injection site reactionsInjection site reactionsYears of ageMonth 13LD vaccineVaccine recipientsSite reactionsHealthy childrenEfficacy studiesChildren 4Placebo-controlled clinical trialUnsolicited adverse eventsFlu-like symptomsLyme disease vaccineHigher immune responseLyme endemic areasOuter Surface ProteinsAdolescents 15 yearsIgG GMTPlacebo recipientsReactogenicity dataAdverse eventsControlled TrialsMonth 6Immunogenicity data